Turnstone Biologics Corp. Common Stock (TSBX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Turnstone Biologics Corp. Common Stock (TSBX) has a cash flow conversion efficiency ratio of -0.292x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.30 Million) by net assets ($14.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Turnstone Biologics Corp. Common Stock (TSBX) total market value for the company's overall valuation and market capitalisation.
Turnstone Biologics Corp. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Turnstone Biologics Corp. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Turnstone Biologics Corp. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Turnstone Biologics Corp. Common Stock ranked by their cash flow conversion efficiency. Explore TSBX cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Praxis Home Retail Limited
NSE:PRAXIS
|
-0.206x |
|
Fiberweb (India) Limited
NSE:FIBERWEB
|
0.085x |
|
Jcurve Solutions Ltd
AU:JCS
|
0.778x |
|
Senti Biosciences Inc
NASDAQ:SNTI
|
-1.163x |
|
Grizzly Discoveries Inc
V:GZD
|
-0.003x |
|
AHT Syngas Technology NV
F:3SQ1
|
0.008x |
|
Northann Corp.
NYSE MKT:NCL
|
-0.204x |
|
PATRYS Ltd
AU:PAB
|
-2.365x |
Annual Cash Flow Conversion Efficiency for Turnstone Biologics Corp. Common Stock (2021–2024)
The table below shows the annual cash flow conversion efficiency of Turnstone Biologics Corp. Common Stock from 2021 to 2024. View Turnstone Biologics Corp. Common Stock (TSBX) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $31.47 Million | $-67.44 Million | -2.143x | -219.65% |
| 2023-12-31 | $98.67 Million | $-66.15 Million | -0.670x | -195.73% |
| 2022-12-31 | $-101.47 Million | $-71.06 Million | 0.700x | +25.63% |
| 2021-12-31 | $-81.85 Million | $-45.63 Million | 0.557x | -- |
About Turnstone Biologics Corp. Common Stock
Turnstone Biologics Corp. operates as a biotechnology company. The company was founded in 2014 and is headquartered in San Diego, California. As of August 11, 2025, Turnstone Biologics Corp. operates as a subsidiary of XOMA Royalty Corporation.